CAG-170: The Hidden Gut Bacterium That Tracks Good Health

CAG-170 is a previously overlooked group of gut bacteria that a 2026 meta-analysis identified as the single most consistent microbial signature of human health, with levels reliably higher in healthy people and reliably lower in people with chronic gut, metabolic, and inflammatory diseases. The study, Meta-analysis of the uncultured gut microbiome across 11,115 global metagenomes reveals a candidate signature of health, was published in Cell Host & Microbe in February 2026 by Dr. Alexandre Almeida’s group at the University of Cambridge. CAG-170 sits inside the so-called “hidden microbiome” — bacteria scientists know only from DNA sequencing, because nobody has yet been able to grow them in a lab. That’s most of what’s been missing from microbiome reports for the last decade.

Key takeaways

• A February 2026 Cell Host & Microbe meta-analysis of 11,115 gut microbiome samples from 39 countries and 13 chronic diseases identified the bacterial genus CAG-170 as the most consistent marker that separates healthy guts from sick ones.
• People with Crohn’s disease, obesity, and chronic fatigue syndrome had lower CAG-170 abundance than healthy controls, per the University of Cambridge research summary.
• CAG-170 is part of the uncultured microbiome — most of these bacteria have never been grown in a lab, so they were invisible to nearly every commercial gut-health test until now.
• The bacteria appear to support the wider microbiome by producing vitamin B12 and enzymes that break down carbohydrates, sugars, and fibers — a “cross-feeding” role that keeps other beneficial microbes alive.
• You cannot buy a CAG-170 probiotic in 2026. The finding is a research milestone, not a supplement label.

What is CAG-170?

CAG-170 is a genus of anaerobic gut bacteria within the Lachnospiraceae family — a large group of fiber-fermenting microbes that are among the most abundant residents of a healthy human colon. The “CAG” prefix stands for co-abundance group, a way researchers name bacterial groups that consistently appear together in gut DNA data even when nobody has cultured them in a Petri dish.

Most consumer gut microbiome reports — Viome, Ombre, ZOE, BIOHM — focus on bacteria that can be grown in labs, because those organisms have decades of supporting literature. CAG-170 has never been on those reports because, until very recently, it had no useful name and no published health association. The 2026 paper changes that: it argues CAG-170 belongs in the conversation alongside Akkermansia muciniphila, Faecalibacterium prausnitzii, and other well-studied “good gut bacteria.”

For the broader context on whether mailing your stool to a sequencing company is currently worth $300, see our piece on whether gut microbiome tests are worth the money in 2026.

What the 2026 study actually found

The Cambridge team pooled 11,115 gut metagenomes from 39 countries spanning North America, Europe, Asia, Africa, and South America. They compared the relative abundance of every detectable microbe across people who were healthy and people diagnosed with one of 13 noncommunicable diseases, including inflammatory bowel disease (Crohn’s and ulcerative colitis), obesity, type 2 diabetes, colorectal cancer, and chronic fatigue syndrome.

Across that dataset, one finding kept reappearing: the genus CAG-170 was the strongest health-associated lineage. It was the most central node in the ecological network of healthy populations, and its abundance was negatively correlated with measures of gut imbalance over time. In plain English: when CAG-170 was high, the rest of the microbiome looked healthier; when it was low, the rest of the community was more often associated with disease.

The lead author summarised it this way in the University of Cambridge press release:

“CAG-170 bacteria — part of the ‘hidden microbiome’ — appear to be key players in human health, likely by helping us to digest the main components of our food and keeping the whole microbiome running smoothly.” — Dr. Alexandre Almeida, University of Cambridge

What’s striking is the consistency across geographies. Gut microbiomes vary enormously between, say, an adult in rural Burkina Faso and an adult in suburban Chicago. Single-species health associations usually wash out as soon as you cross a continent. CAG-170’s association held in every region the team examined.

Why scientists missed CAG-170 until now

A large fraction of human gut bacterial species have never been successfully cultured in a lab. Conventional microbiology starts by growing a microbe in a dish and characterising what it does. If a bug refuses to grow, it gets a code name from its DNA and is shelved for later.

CAG-170 is a textbook example. Researchers can read its genome out of stool DNA — they can see what enzymes it likely produces and what nutrients it likely consumes — but nobody has yet coaxed most CAG-170 species into a Petri dish. That means:

• No published probiotic trials.
• No “CAG-170 boosting” supplement, anywhere, in 2026.
• No mention of it in most consumer microbiome reports.

The 2026 paper used DNA sequencing on a global scale to bypass the culture step entirely. That’s also why this work is interesting beyond CAG-170 itself: it suggests the next generation of useful gut bacteria probably lives in the part of the microbiome we still can’t grow.

What CAG-170 actually does in your gut

The Cambridge group reconstructed CAG-170’s likely functions from its genome. Two stood out:

It produces vitamin B12

CAG-170 carries the genetic machinery to synthesize vitamin B12 (cobalamin), a vitamin essential for nerve function, red blood cell formation, and DNA synthesis. Humans don’t make B12 themselves. We absorb it from animal foods or fortified products, primarily in the ileum — the last part of the small intestine.

A wrinkle worth flagging: most B12 produced by gut bacteria is generated in the colon, downstream of where humans absorb it. So your CAG-170 B12 is unlikely to feed you directly. Instead, it likely feeds other gut bacteria that depend on B12 to do their jobs — a process called microbial cross-feeding. Many beneficial gut bacteria lack the ability to make B12 themselves and would struggle to thrive without a CAG-170-like benefactor.

It breaks down a wide range of plant fibers

CAG-170 species encode enzymes that degrade diverse dietary carbohydrates — starches, sugars, and plant fibers that humans can’t digest on their own. Fiber fermentation in the colon produces short-chain fatty acids like butyrate, which feed colonocytes (the cells lining the colon) and have been linked to reduced inflammation. Lachnospiraceae bacteria more broadly are well known as major fiber fermenters, per a 2024 review in PMC, and CAG-170 appears to be a particularly versatile member of that family.

The combined picture: CAG-170 looks like a behind-the-scenes utility, fermenting fiber, generating B12, and supporting other bacteria. That fits the broader pattern in microbiome research that the function of the community matters more than any single named species.

Should you try to “boost” your CAG-170 levels?

There is no validated way to raise your CAG-170 in 2026. But the indirect strategies that support Lachnospiraceae more broadly are not new and not surprising:

• Eat a wide variety of plant fibers. Lachnospiraceae feed on diverse fermentable substrates. The single best diet predictor of microbiome diversity in repeated studies is the number of distinct plant species in your weekly intake. See fiber and stool consistency for the practical fiber targets.
• Eat fermentable fibers specifically. Soluble and fermentable fibers — beans, oats, barley, onions, garlic, leeks, apples, slightly green bananas — feed the bacteria that make short-chain fatty acids. See probiotics vs prebiotics for how prebiotic fibers work.
• Avoid unnecessary antibiotic exposure. Antibiotic courses temporarily wipe out a chunk of the Lachnospiraceae family. Most species bounce back, but full microbiome recovery can take months to years, per our deeper review of antibiotics and gut microbiome recovery.

What you should not do is buy a “CAG-170 probiotic.” Nobody is selling one. Any product claiming to contain CAG-170 in 2026 is mislabelled — most of these bacteria can’t be grown into a capsule yet.

What CAG-170 means for your daily stool tracking

The CAG-170 discovery is a research milestone, not an at-home test. You can’t know your CAG-170 abundance without sending a sample to a research-grade sequencing lab, and even the high-end consumer tests don’t reliably resolve it yet.

But the finding reinforces a more useful daily habit: track the outputs of a healthy microbiome, not just hypothetical species counts. The classic markers — regular Bristol Type 3–4 stools, normal brown color, steady frequency, low gas, no urgency — reflect the function of the whole gut community, which is exactly the level CAG-170 research suggests matters most.

The PoopCheck app classifies each bowel movement by Bristol type, color, and consistency over time, so you can spot when your gut is consistently in the healthy zone or drifting out of it — long before any sequencing result would tell you.

CAG-170 and the next wave of microbiome biomarkers

CAG-170 is not the first uncultured genus to be flagged as a health marker, and it won’t be the last. The 2026 paper is part of a broader move in microbiome science to look beyond the species we’ve already named. Other work along the same lines includes:

• The University of Geneva AI stool test that resolves gut bacteria at the subspecies level to detect colorectal cancer with ~90% sensitivity, also published in Cell Host & Microbe.
• The 2025 Nature identification of imidazole propionate (ImP) as a gut-metabolite driver of heart disease — a parallel “single microbial signal as systemic biomarker” story for the cardiovascular system.
• Ongoing efforts to culture previously unculturable bacteria using new growth media, robotic colony pickers, and host-mimicking conditions.

Expect the consumer testing market to incorporate uncultured bacteria like CAG-170 into reports over the next few years, and to make claims about them that may or may not match the evidence. The 2026 finding is real and well-powered; turning it into a useful supplement is the part nobody has done yet.

FAQ

Is CAG-170 a probiotic I can buy?

No. As of mid-2026, CAG-170 has not been cultured into a commercial probiotic. Anything claiming to contain “CAG-170” today is either mislabelled or referencing the research without delivering the actual bacteria.

What does the “CAG” in CAG-170 stand for?

CAG stands for co-abundance group. It’s a label researchers use for bacterial groups that consistently show up together in DNA-sequencing data, even when individual species haven’t been formally named or grown in a lab.

How is CAG-170 different from Akkermansia or Faecalibacterium?

Akkermansia muciniphila and Faecalibacterium prausnitzii are well-studied health-associated bacteria that can be grown in labs, so they have years of mechanistic research and commercial probiotic trials behind them. CAG-170 is in the same “good gut bacteria” tier statistically but mostly remains uncultured, so the lab work is years behind the data.

Will a microbiome test tell me my CAG-170 level?

Most consumer tests in 2026 don’t reliably resolve CAG-170 because their reference databases and reporting categories were built before the 2026 paper. Some research-grade shotgun metagenomics tests can detect it, but the result has no actionable interpretation today — there’s nothing specific you can do to raise it that you weren’t already doing for gut health generally.

Does diet change my CAG-170 levels?

The 2026 paper didn’t run a diet intervention, so the direct answer is “not proven.” But CAG-170 belongs to the Lachnospiraceae family, which broadly responds to a high-fiber, plant-diverse diet. Eating a wide range of plant fibers is the best bet for supporting the family as a whole.

Why did it take so long to discover CAG-170?

A large fraction of human gut bacteria have never been cultured in a lab, and CAG-170 was invisible to traditional microbiology because nobody could grow it. The 2026 finding was only possible because DNA sequencing now lets researchers identify and track bacteria from their genetic fingerprints alone, without ever growing them.

The takeaway

CAG-170 looks like a real, robust marker of a healthy human gut — the most consistent one identified to date across 39 countries and 13 diseases. But for now, it’s a research finding, not a recipe. The practical implication for daily gut health hasn’t shifted: eat a wide range of plants, get enough fiber, avoid unnecessary antibiotics, and watch the actual outputs — Bristol type, color, frequency, urgency. That’s the part of your gut you can read every day, no sequencing required. If you want to do that systematically, PoopCheck is built around exactly that habit.

Sources

1. Almeida, A. et al. Meta-analysis of the uncultured gut microbiome across 11,115 global metagenomes reveals a candidate signature of health. Cell Host & Microbe, February 2026. https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(26)00038-7
2. University of Cambridge. “Hidden” bugs in our gut appear key to good health, finds global study. February 2026. https://www.cam.ac.uk/research/news/hidden-bugs-in-our-gut-appear-key-to-good-health-finds-global-study
3. ScienceDaily. Scientists discover a hidden gut bacterium linked to good health. February 11, 2026. https://www.sciencedaily.com/releases/2026/02/260211204210.htm
4. Vacca, M. et al. The Controversial Role of Human Gut Lachnospiraceae. Microorganisms, 2020. https://www.mdpi.com/2076-2607/8/4/573
5. Sorbara, M.T. & Pamer, E.G. Lachnospiraceae are emerging industrial biocatalysts and biotherapeutics. Frontiers in Bioengineering, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10794557/